ニューヨークにおける鎌状赤血球症の臨床試験
ニューヨーク内の拠点で、鎌状赤血球症に関する21件の研究が参加者を募集しています。
ニューヨーク内の都市
公式研究テキスト（英語）
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Childrens Hospital at Montefiore, The Bronx
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/09/28更新 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Mount Sinai Hospital, New York
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Columbia University Medical Center_New York_0, New York
- Columbia University Medical Center_New York_0, New York
被験者募集中第3相
2歳以上 · 全性別 · 2026/09/18更新 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- NYC Health+Hospitals, Brooklyn
- Interfaith Medical Center, Brooklyn
- Cohen Children's Medical Ctr, Queens
- 他2件
被験者募集中第3相
12歳以上 · 全性別 · 2026/09/17更新 · NCT06612268A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Icahn School of Medicine at Mount Sinai, New York
- Jacobi Medical Center, The Bronx
被験者募集中第2/3相
12歳以上 · 全性別 · 2026/08/18更新 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Western New York BloodCare, Buffalo
- Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center, Hyde Park
- Weill Cornell Medical College - New York Presbyterian Hospital, New York
- 他2件
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/17更新 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Mount Sinai Medical Center, New York
- Jacobi Medical Center, The Bronx
被験者募集中第2相
12歳以上 · 全性別 · 2026/08/14更新 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Jacobi Medical Center, The Bronx
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07224360The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Richmond University Medical Center- Site Number : 8400038, Staten Island
- Montefiore Medical Center - Moses Campus- Site Number : 8400057, The Bronx
被験者募集中第3相
10歳〜65歳 · 全性別 · 2026/07/29更新 · NCT06975865Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- New York Medical College, Valhalla
被験者募集中第2相
6 Months – 21 Years · 全性別 · 2026/07/27更新 · NCT02675959Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering, New York
被験者募集中第1/2相
12歳〜50歳 · 全性別 · 2026/07/02更新 · NCT04819841131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
- Columbia University Irving Medical Center, New York
被験者募集中第1相
12歳〜50歳 · 全性別 · 2026/06/10更新 · NCT07015684Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Roswell Park (MRD-HCT), Buffalo
- Columbia Presbytarian (NT-DMT), New York
- Cohen's Children Hospital (NT-DMT), Queens
- 他4件
被験者募集中観察研究
3歳〜20歳 · 全性別 · 2026/06/04更新 · NCT06941389A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- Memorial Sloan Kettering Suffolk - Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre
被験者募集中第2相
2歳〜50歳 · 全性別 · 2026/06/03更新 · NCT05736419Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York
被験者募集中第3相
12歳〜35歳 · 全性別 · 2026/03/23更新 · NCT05477563Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Columbia University, New York
被験者募集中第2相
2歳〜25歳 · 全性別 · 2026/03/10更新 · NCT03587272A Long-term Follow-up Study in Patients Who Received BEAM-101
- Columbia University Irving Medical Center, New York
被験者募集中観察研究
14歳〜37歳 · 全性別 · 2026/01/28更新 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Weil Cornell Medical College, New York
- University of Rochester Medical Center, Rochester
被験者募集中
16歳〜30歳 · 全性別 · 2026/01/07更新 · NCT06374238Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
- Mount Sinai Hospital, New York
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05519111AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- New York Medical College, Valhalla
被験者募集中第2相
1 Day – 30 Years · 全性別 · 2025/08/08更新 · NCT04099966Cannabidiol in Sickle Cell Disease
- Icahn School of Medicine at Mount Sinai, Manhattan
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/06/25更新 · NCT06930703ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。